Sandra Galarza-Vargas, MD
Pulmonary Disease · Ponce, PRNPI 1154585255
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,588 and has fallen 57.3% since, to $677 in 2025.
Across 156 payments — averaging $42.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Bayer$656
- United Therapeutics Corporation$456
- Johnson & Johnson$451
- Boehringer Ingelheim$273
- plus $2K from 21 others
What the payments were for
- Travel & lodging$160%
- Food & beverage$6,51899%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $1,514 |
| GSK | 20 | $1,156 |
| Bayer | 17 | $656 |
| United Therapeutics Corporation | 5 | $456 |
| Johnson & Johnson | 11 | $451 |
| Boehringer Ingelheim | 9 | $273 |
| Boston Scientific | 2 | $228 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $187 |
| Grifols USA, LLC | 1 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $164 |
| BD | 2 | $129 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Bard Peripheral Vascular, Inc. | 1 | $124 |
| Olympus Latin America, Inc. | 4 | $105 |
| W. L. Gore & Associates, Inc. | 1 | $100 |
| Mylan Specialty L.p. | 1 | $97 |
| Lilly USA, LLC | 1 | $97 |
| Mallinckrodt Enterprises LLC | 1 | $95 |
| Genentech USA, Inc. | 3 | $88 |
| Sanofi-aventis U.S. LLC | 3 | $71 |
| Jazz Pharmaceuticals Inc. | 3 | $63 |
| Mylan LLC | 3 | $44 |
| Chiesi USA, Inc. | 2 | $39 |
| Medtronic | 1 | $33 |
| Sanofi | 2 | $33 |
| Shire North American Group Inc | 2 | $28 |
| PBG Puerto Rico LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$372
- TRELEGY ELLIPTA$341
- TEZSPIRE$250
- FASENRA$250
- TYVASO$249
- Kerendia$228
- Prolastin-C$177
- WATCHMAN FLX$133
- GLASSIA$125
- CAMZYOS$125
- XARELTO$105
- GORE BIO-A Tissue Reinforcement$100
How this compares
$6,553 in reported general payments places this provider in the 80th percentile of 138 pulmonary disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 28 | $102,146 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $32,478 |
| Spiriva RespimatTiotropium Bromide | 46 | $24,592 |
| Fluticasone Propionate HfaFluticasone Propionate | 75 | $19,298 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $14,424 |
| Atrovent HfaIpratropium Bromide | 23 | $10,986 |
| Wixela InhubFluticasone Propion/Salmeterol | 24 | $7,511 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,932 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $5,702 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,384 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,384 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 92 | $4,091 |
| Fluticasone Propionate | 149 | $3,464 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,124 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 33 | $1,756 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $1,156 | $157,555131 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $273 | $29,97557 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Ponce
- Domingo Chardon FelicianoPonce$45K
- George FahedPonce$16K
- Giovanni Veloz IrizarryPonce$11K
- Dev Boodoosingh CasianoPonce$10K
- Jesse Aleman-OrtizPonce$10K
- Keren Mendez RamirezPonce$8K
- Hector Puig-RamirezPonce$8K
- Ilean Lamboy HernandezPonce$5K
- Eugenio Rivera RiosPonce$3K
- Manuel Morell CataquetPonce$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.